Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationDepreciation & Amortization (IS)EBIATLeasesLong-Term Debt RepaymentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Shares IssuedShort-Term Debt issuancesShort-Term Debt repayments
Ratios

Rxo (RXO) Short-Term Debt repayments (2023 - 2025)

Historic Short-Term Debt repayments for Rxo (RXO) over the last 3 years, with Q4 2025 value amounting to $95.0 million.

  • Rxo's Short-Term Debt repayments rose 18787.88% to $95.0 million in Q4 2025 from the same period last year, while for Dec 2025 it was $533.0 million, marking a year-over-year increase of 13584.07%. This contributed to the annual value of $533.0 million for FY2025, which is 13584.07% up from last year.
  • According to the latest figures from Q4 2025, Rxo's Short-Term Debt repayments is $95.0 million, which was up 18787.88% from $211.0 million recorded in Q3 2025.
  • In the past 5 years, Rxo's Short-Term Debt repayments registered a high of $265.0 million during Q1 2025, and its lowest value of -$38.0 million during Q2 2025.
  • Its 3-year average for Short-Term Debt repayments is $92.2 million, with a median of $71.0 million in 2023.
  • Within the past 5 years, the most significant YoY rise in Rxo's Short-Term Debt repayments was 75483.87% (2025), while the steepest drop was 16229.51% (2025).
  • Rxo's Short-Term Debt repayments (Quarter) stood at $71.0 million in 2023, then plummeted by 53.52% to $33.0 million in 2024, then skyrocketed by 187.88% to $95.0 million in 2025.
  • Its Short-Term Debt repayments stands at $95.0 million for Q4 2025, versus $211.0 million for Q3 2025 and -$38.0 million for Q2 2025.